Showing 231 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Long-term Extension Study of Ligelizumab in Food Allergy

Food Allergy Phase 3 United States

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Macular Polypoidal Choroidal Vasculopathy (PCV) Phase 3 Korea, Republic of

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 2 China

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP) Phase 3 United States
Spain
Czech Republic
Belgium
Romania
Hungary
France
Germany
Japan
Norway
Hong Kong
Malaysia
Australia
Singapore
United Kingdom
View All

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Primary Immune Thrombocytopenia Phase 3 United States
Turkey
Spain
China
Czech Republic
Hungary
Germany
Norway
Korea, Republic of
Malaysia
Austria
United Kingdom
Japan
Belgium
Singapore
Netherlands
View All

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia (wAIHA) Phase 3 Italy
Thailand
Spain
France
Romania
Hungary
Germany
China
Japan
Malaysia
United Kingdom
Australia
Singapore
View All

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Systemic Lupus Erythematosus Phase 3 Spain
China
United States
Japan
Hungary
View All

Kesimpta (Ofatumumab) Pregnancy Registry

Multiple Sclerosis, Pregnancy United States

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Advanced Breast Cancer Phase 4 India

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Paroxysmal Nocturnal Hemoglobinuria Phase 3 United States